An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
The new site enables end-to-end production of viral vector gene therapies
Ultra-high purity surfactant for biologics and parenteral drug formulations
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Subscribe To Our Newsletter & Stay Updated
